Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Patent metadata

Field	Value
Publication number	US-11021460-B2
Application number	US-201916577946-A
Country	US
Kind code	B2
Filing date	Sep 20, 2019
Priority date	Dec 11, 2016
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.

First claim

We claim:

1. A method of providing a stimulant based treatment modality and dosage form for an eating disorder or a binge eating disorder, wherein the method comprises administering a composition comprising a compound to a subject in need thereof, wherein the compound is a conjugate of d-methylphenidate having the following chemical formula:

salts thereof, or mixtures thereof.

2. The method of claim 1 , wherein the salt of the compound is at least one pharmaceutically or therapeutically acceptable salt form or salt mixture thereof.

3. The method of claim 2 , wherein the at least one pharmaceutically or therapeutically acceptable salt form is independently selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, martrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, and undecylenate.

4. The method of claim 2 , wherein the at least one pharmaceutically or therapeutically acceptable salt form of the compound is independently selected from the group consisting of chloride, hydrochloride, hydrogen carbonate (bicarbonate), iodide, bromide, citrate, acetate, formate, salicylate, hydrogen sulfate (bisulfate), hydroxide, nitrate, hydrogen sulfite (bisulfite), propionate, benzene sulfonate, hypophosphite, phosphate, bromate, iodate, chlorate, fluoride, and nitrite.

5. The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a thin strip, an oral thin film (OTF), an oral strip, a rectal film, a syrup, a suspension, and a suppository.

6. The method of claim 5 , wherein the dosage form is administered orally.

7. The method of claim 5 , wherein the composition has a dosing regimen that is selected from the group consisting of about four times a day or less, about three times a day or less, about two times a day or less, and about one time a day.

8. The method of claim 7 , wherein the composition has a dosing regimen that is about one time a day.

9. The method of claim 1 , wherein the composition provides a dose amount that is the molar equivalent to a dose from about 0.1 mg to about 500 mg d-methylphenidate hydrochloride per dose.

10. The method of claim 1 , wherein the composition is provided in a unit dose form, blister pack, roll, or bulk bottle.

11. The method of claim 10 , wherein the unit dose form provides an amount of d-methylphenidate that is molar equivalent to about 0.5 mg to about 500 mg d-methylphenidate hydrochloride.

12. The method of claim 1 , wherein the composition further comprises one or more excipients or one or more additional pharmaceutically active ingredients.

13. The method of claim 12 , wherein the excipients are selected from the group consisting of antiadherents, binders, coatings, disintegrants, gel forming agents, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents and sweeteners.

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Chi Guochen

Classifications

• C07D211/34 Primary

  with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61P25/36

  Opioid-abuse · CPC title

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title